n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney disease by Barden, A. et al.




Anne Barden, Nathan O'Callaghan, Valerie Burke, Emile Mas, Lawrence J. Beilin, Michael Fenech, 
Ashley B. Irish, Gerald F. Watts, Ian B. Puddey, Rae-Chi Huang and Trevor A. Mori 
n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney 
disease 
Nutrients, 2016; 8(3):1-11 
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license 
(http://creativecommons.org/licenses/by/4.0/). 































n-3 Fatty Acid Supplementation and Leukocyte
Telomere Length in Patients with Chronic
Kidney Disease
Anne Barden 1,*, Nathan O’Callaghan 2, Valerie Burke 1, Emile Mas 1, Lawrence J. Beilin 1,
Michael Fenech 2, Ashley B. Irish 3, Gerald F. Watts 1, Ian B. Puddey 1, Rae-Chi Huang 4,†
and Trevor A. Mori 1,†
1 School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000,
Western Australia, Australia; valerie.burke@uwa.edu.au (V.B.); emilie.mas@sa.gov.au (E.M.);
lawrie.beilin@uwa.edu.au (L.J.B.); gerald.watts@uwa.edu.au (G.F.W.); ian.puddey@uwa.edu.au (I.B.P.);
trevor.mori@uwa.edu.au (T.A.M.)
2 CSIRO Food and Nutrition, Adelaide 5000, South Australia, Australia;
nathan.OCallaghan@csiro.au (N.O.C.); Michael.Fenech@csiro.au (M.F.)
3 Department of Nephrology and Transplantation, Fiona Stanley Hospital, Murdoch 6150, Western Australia,
Australia; Ashley.Irish@health.wa.gov.au
4 Telethon Kids Institute, Subiaco 6008, Western Australia, Australia; Rae-Chi.Huang@telethonkids.org.au
* Correspondence: anne.barden@uwa.edu.au; Tel.: +61-8-9224-0272
† These authors contributed equally to this work.
Received: 17 December 2015; Accepted: 17 March 2016; Published: 19 March 2016
Abstract: DNA telomere shortening associates with the age-related increase cardiovascular disease
(CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD
risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10
(CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five
CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control
(4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood
mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts.
Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting
for baseline values. F2-isoprostanes were measured as markers of oxidative stress. There was no
effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length
corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention
plasma F2-isoprostanes were negative predictors of post-intervention telomere length corrected for
neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for
neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with
shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in
CKD patients.
Keywords: neutrophils; telomere length; oxidative stress; n-3 fatty acids; coenzyme Q10
1. Introduction
Telomeres are chromatin structures that cap the ends of chromosomes and preserve genome
stability. At a cellular level, loss of telomeric DNA eventually leads to cell death or senescence. A
major factor contributing to telomere damage is oxidative stress that promotes telomere erosion during
cellular replication and stimulates synthesis of inflammatory cytokines [1,2]. Telomere shortening
has been associated with the age-related increase in risk of chronic conditions such as cancer and
cardiovascular disease (CVD). Patients with chronic kidney disease (CKD) and those receiving dialysis
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have a greatly increased risk of CVD. There is data from a longitudinal study of patients with
stable coronary heart disease suggesting shorter baseline telomere length is associated with lower
glomerular filtration rate (GFR) [3]. Patients receiving haemodialysis have shorter telomeres and
accelerated telomere shortening compared with the general population [4,5]. Telomere attrition
associates with inflammation, low fetuin–A levels and increased mortality in CKD patients undergoing
haemodialysis [6].
Telomere length is in part determined by cellular telomerase activity. Telomerase is a
ribonucleoprotein that synthesises telomeres and can compensate for the loss of telomeres during
cell division. Telomerase activity in hematopoietic progenitor cells determines the telomere length of
circulating leukocytes. Mature neutrophils and monocytes differ from lymphocytes in that they do not
undergo further cell division as they circulate and they are devoid of telomerase activity.
Population studies have shown that there is substantial variability in the rate of telomere
shortening that is independent of chronological aging, suggesting that telomere loss may be a
modifiable factor [7,8]. A number of lifestyle and dietary factors have been examined as possible
determinants of telomere shortening in cross-sectional trials as well as animal studies. Smoking
and obesity associate with telomere shortening while dietary restriction, increasing dietary fibre or
anti-oxidants, or reducing fat or protein intake protect against telomere shortening [9]. Other factors
that may affect telomere length include leukocyte cell counts that positively associate with telomere
length [10–12]. This may be particularly relevant in patients with CKD whose neutrophil cell counts
have been shown to be elevated, likely as a result of increased apoptosis [13]. Interventions aimed at
reducing oxidative stress have been suggested as a possible way of inhibiting telomere shortening.
Studies in humans have shown that oxidative stress, as assessed by plasma and urinary
F2-isoprostanes, is reduced by supplementation with n-3 fatty acids [14–16]. Another potential
modifier of oxidative stress is coenzyme Q10 (CoQ) an intracellular antioxidant that protects membrane
phospholipids, mitochondrial membrane protein, low-density lipoprotein and lymphocyte DNA from
free radical-induced oxidative damage [17–19]. As oxidative stress is regarded as a major contributor
to risk of CVD in patients with CKD [20], the implementation of interventions using n-3 fatty acids
and/or CoQ are therefore considered possible modifiers of oxidative stress that might inhibit telomere
shortening and have the potential to modify CVD risk. The only other study examining the effect of
n-3 fatty acids on oxidative stress in predialysis patients was uncontrolled, of short duration (2 weeks),
with small numbers of patients (n = 5) and assessed oxidative stress using a method that is known to
be non-specific. [21]
In a randomized controlled trial that examined the main and additive effects of n-3 fatty acids
and coenzyme Q10 (CoQ) on cardiovascular risk in patients with CKD we showed that n-3 fatty
acid supplementation reduced blood pressure, heart rate and plasma triglycerides [22]. This report
examines the effects of n-3 fatty acids and CoQ on telomere length of DNA from neutrophils and
mononuclear cells of patients CKD from that study.
2. Volunteers and Methods
2.1. Participants
Eighty five men and women aged 25–75 years with chronic renal impairment (defined as an
estimated (e) GFR >15 and <60 mL/ min/1.73 m2 and serum creatinine <350 mmol/L), were recruited
between March 2004 and October 2006 from the renal units of Royal Perth, Sir Charles Gairdner
and Fremantle Hospitals, in Perth, Western Australia,. Exclusion criteria included: diabetes; angina
pectoris; major surgery, a cardiovascular event or symptoms of CVD <3 months; BP >170/100 mmHg;
liver disease; nephrotic syndrome (proteinuria >3 g/day or protein/creatinine ratio >300 mg/mmol);
and haemoglobin <110 g/L. Patients were also excluded if they were smokers; regularly took
non-steroidal anti-inflammatory or immunosuppressive drugs; nitrates; the phosphodiesterase
inhibitor sildenafil; ate >1 fish meal/week or regularly took fish oil supplements; or if they consumed
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an average >4 standard alcoholic drinks/day. Antihypertensive and lipid-lowering medication were
not exclusion criteria. All patients gave informed written consent and the trial was approved by the
ethics committee of Royal Perth Hospital, Sir Charles Gairdner and Fremantle Hospitals. The trial was
registered with the Australian and New Zealand Clinical Trials Registry (ACTRN012605000088640)
and conducted in accordance with the Declaration of Helsinki.
2.2. Study Design
The trial was double-blind and placebo-controlled. Patients maintained their usual dietary
habits during a 3-week familiarization period. After baseline measurements were obtained they were
stratified by age and BMI, and randomly allocated by the statistician using computer-generated random
numbers to one of four study groups: n-3 fatty acids (4 g daily, Omacor, Solvay Pharmaceuticals,
Pymble, NSW, Australia), CoQ (200 mg daily, Blackmores Australia (Balgowlah, NSW, Australia),
the two combined (n-3 fatty acids + CoQ), or control (4 g daily olive oil, Cardinal Health Australia,
Braeside, Victoria, Australia), for 8 weeks, The allocation sequence was concealed using numbered
containers until interventions were assigned at the time of enrolment by study personnel not involved
in the process. Capsules of n-3 fatty acids contained 460 mg eicosapentaenoic acid (EPA, 20:5 n-3),
38 mg docosapentaenoic acid (DPA, 22:5 n-3) and 380 mg docosahexaenoic acid (DHA, 22:6, n-3).
Patients took 2 ˆ 1 g n-3 fatty acid or control, and 2 ˆ 50 mg CoQ or placebo capsules, twice daily with
meals. They were asked to maintain their usual diets and lifestyle during the intervention. Compliance
with the supplements was monitored by measurement of platelet fatty acids and plasma CoQ.
2.3. Measurement of Leukocyte Telomere Length and Plasma F2-Isoprostanes
Blood samples and a 24 h urine collection were obtained at baseline and at the end of the eight
week intervention. Peripheral blood mononuclear cells (PBMC) and neutrophils were isolated from
venous blood by density gradient centrifugation using Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden), cell counts were measured using the Technicon H1 Analyser (Bayer Diagnostics, Sydney,
Australia) and neutrophils and PBMC were prepared for cryopreservation in fetal bovine serum (FBS)
plus 10% DMSO, prior to storage in liquid nitrogen until required. DNA isolation used a QIAGEN
DNeasy Kit with minor modifications to prevent DNA oxidation [23]. Absolute telomere length (aTl)
of DNA from PBMC or neutrophils was measured by determining the number of TTAGGG hexamer
repeats using quantitative real-time PCR (qPCR) as previously described [22]. The method is based on
the qPCR technique described by Cawthon [24] to measure relative telomere length (rTL) but modified
by using a standard curve generated with serial dilution of a synthetic telomere repeat sequence
oligomer. The standard curve was used to convert rTL values to aTL data which are reported as
kb/diploid genome. The assays were done in duplicate and the inter- and intra-experimental variation
was less than 7%. Plasma F2-isoprostanes were measured by gas chromatography-mass spectrometry
as previously described [25]. High sensitivity C-reactive protein (hs-CRP) was measured using a
high sensitivity monoclonal antibody assay (Dade Behring Marburg GmbH, Marburg, Germany) as
previously described [26].
2.4. Statistical Analysis
Analyses included only participants who completed the trial. Sample size was based on the
primary endpoint of blood pressure [22]. The study had an 80% power to detect a 3 mm Hg difference
in ambulatory systolic blood pressure at p < 0.05. Post-intervention data were analysed using SPSS15.0
(SPSS Inc., Chicago, Illinois, IL, USA) or SAS 9.0 (SAS Inc., Chicago, Illinois, IL, USA) with general
linear models adjusting for baseline values and assessing main and interactive effects of n-3 fatty acids
and CoQ. Baseline measures were compared by one-way analysis of variance. Significance levels
were adjusted for multiple comparisons by the Tukey test. Values are means (SEM) or geometric
mean (95% confidence interval (CI)). In order to account for any potential confounding effects of the
treatments on leukocyte cell counts that may have influenced DNA telomere length [10–12], analyses
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were performed on neutrophil DNA telomere length corrected for neutrophil cell count or PBMC
DNA telomere length corrected for PBMC cell count. Regression models were used to explore the
relationship between plasma F2-isoprostanes and telomere length.
3. Results
Eighty-five patients aged 56.5 ˘ 1.4 years, with BMI 27.3 ˘ 0.5 kg/m2, supine BP
125.0 ˘ 1.7/72.3 ˘ 0.9 and eGFR 35.8 ˘ 1.2 mL/min/1.73 m2 were randomized to the four groups.
Seventy-four patients completed the study. The consort diagram for this clinical trial has been
published [22]. DNA from neutrophils and PBMCs was available from 73 of the 74 patients: control
(n = 15); n-3 fatty acids (n = 19); CoQ (n = 21) and n-3 fatty acids + CoQ (n = 18). Bodyweight and eGFR
were similar at baseline in the 4 groups and did not change significantly during the intervention [22].
Antihypertensive medication was taken by 72 of the 74 patients and did not change throughout the
study. At baseline, 74% of patients allocated to n-3 fatty acids were taking angiotensin converting
enzyme inhibitors compared with 75% of those allocated to the control oil [22].
The study showed good compliance with n-3 fatty acid and CoQ intake. Platelet long chain n-3
fatty acids (20:5 + 22:5 + 22:6) increased from baseline by 6.4% ˘ 1% (p < 0.001) in the n-3 fatty acid
group and by 5.4% ˘ 1.1% (p < 0.001) in the n-3 fatty acid + CoQ group compared with the control and
CoQ groups. Plasma CoQ levels increased in the CoQ group by 3260 ˘ 351 nmol/L (p < 0.001) and by
2114 ˘ 286 nmol/L (p < 0.001) in the n-3 fatty acid+CoQ group, compared with the control and n-3
fatty acid groups. There were no reported side effects of the supplements in any group.
At baseline neutrophil counts in the groups were: Controls, 3.8 ˘ 0.2 ˆ 109 cells/L; n-3 fatty acid,
3.1 ˘ 0.2 ˆ 109 cells/L; CoQ, 3.9˘ 0.3 ˆ 109 cells/L; and n-3 fatty acid + CoQ. 4.0˘ 0.2 ˆ 109 cells/L. Post
intervention neutrophil counts adjusted for baseline were not different between the groups (p = 0.174).
At baseline, PBMC counts were not different between the groups: Controls, 2.0 ˘ 0.1 ˆ 109 cells/L;
n-3 fatty acid, 2.2 ˘ 0.1 ˆ 109 cells/L; CoQ, 2.2 ˘ 0.1 ˆ 109 cells/L; and n-3 fatty acid + CoQ. 2.2 ˘ 0.1 ˆ 109 cells/L
and were unaffected by the interventions.
3.1. Telomere Length at Baselinein Patients with CKD
At baseline, neutrophil telomere length was not different between the groups (Table 1). However,
PBMC telomere length was significantly shorter in the n-3 fatty acid + CoQ group compared with the
group allocated to take CoQ alone (p = 0.03, Table 1). In the groups combined, baseline neutrophil
telomere length was not significantly associated with PBMC telomere length (r = 0.173, p = 0.149).
There were no significant associations between neutrophil or PBMC telomere length and age, BMI,
eGFR, gender, platelet n-3 fatty acids, hs-CRP or plasma F2-isoprostanes at baseline.
3.2. Effect of n-3 Fatty Acids and CoQ on Telomere Length
After 8 weeks of intervention there were no significant main or interactive effects of n-3 fatty
acids or CoQ on neutrophil or PBMC telomere length (Table 1). Post-intervention telomere length in
neutrophils and PBMC were not significantly related.
3.3. Effect of n-3 Fatty Acids and CoQ on Telomere Length Corrected for Cell Count
Neutrophil telomere length was not significantly associated with neutrophil count at baseline but
was positively associated with neutrophil count after the intervention (r = 0.317, p = 0.006). In order
to account for any potential confounding effects of the treatments on leukocyte cell counts that may
have influenced DNA telomere length [10–12], analyses were performed on neutrophil DNA telomere
length corrected for cell count. Neutrophil telomere length corrected for neutrophil count was not
significantly different between the groups at baseline, but was increased in a main effect analysis that
compared patients after n-3 fatty acids (0.19 ˘ 0.17 kb/genome/105 cells, p = 0.015) with those that
did not receive n-3 fatty acids, adjusting for baseline values (Table 1, Figure 1A). The effect of n-3 fatty
acids remained significant after adjusting for age, gender and BMI (p = 0.008). In contrast, CoQ did not
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significantly alter neutrophil telomere length after correcting for neutrophil cell count (´0.10 ˘ 0.07,
p = 0.17, for main effect). There was no significant interaction between n-3 fatty acids and CoQ that
affected neutrophil telomere length (Table 1).
Table 1. Neutrophil and peripheral blood mononuclear cells (PBMC) telomere length before and after







n-3 FA + CoQ
(n = 18)
ANOVA at Baseline (p Value) Interaction
(p Value)Main Effects (p Value)
n-3 FA CoQ
Neutrophil telomere length (kb/genome)
Baseline 163.4 ˘ 21.5 159.1 ˘ 16.1 181.2 ˘ 14.3 149.7 ˘ 12.3 NS
Post 166.9 ˘ 11.5 160.9 ˘ 10.3 155.6 ˘ 9.8 184.8 ˘ 10.6 29.3 ˘ 14.6 24.6 ˘ 14.7
(p = 0.28) (p = 0.54) p = 0.1
Neutrophil telomere length corrected for neutrophil count (kb/genome/105 cells)
Baseline 0.61 ˘ 0.10 0.82 ˘ 0.12 0.97 ˘ 0.18 0.55 ˘ 0.06 p = 0.25
Post 0.72 ˘ 0.08 0.91 ˘ 0.70 0.63 ˘ 0.07 0.82 ˘ 0.08 0.19 ˘ 0.07 ´0.10 ˘ 0.07
(p = 0.015) (p = 0.17) p = 0.97
PBMC telomere length (kb/genome)
Baseline 103.9 ˘ 11.6 86.5 ˘ 11.4 114.1 ˘ 9.8 75.0 ˘ 8.2 * p = 0.03
Post 107.1 ˘ 11.6 101.9 ˘ 10.2 96.5 ˘ 9.7 107.3 ˘ 10.5 10.5 ˘ 14.7 5.1 ˘ 14.5
(p = 0.48) (p = 0.73) p = 0.46
PBMC telomere length corrected for PBMC count (kb/genome/105 cells)
Baseline 1.06 ˘ 0.14 0.89 ˘ 0.13 1.18 ˘ 0.14 0.66 ˘ 0.11 * p = 0.03
Post 1.16 ˘ 0.15 0.95 ˘ 0.14 0.99 ˘ 0.13 1.08 ˘ 0.14 ´0.64 ˘ 0.14 ´0.02 ˘ 0.14
(p = 0.9) (p = 0.73) p = 0.29
Values expressed as mean ˘ SEM. n-3 FA = n-3 fatty acid supplementation. Post = post-intervention data
adjusted for baseline values. Baseline measures were compared by one-way ANOVA. General linear models
were used to assess main effects and interactions of n-3 fatty acids and Coenzyme Q10 (CoQ) on post-intervention
values adjusted for baseline value. Significance levels were adjusted for multiple comparisons by the Tukey
test. * p < 0.05 for baseline difference between patients allocated to n-3 fatty acids + CoQ compared with those




















Baseline  163.4 ± 21.5  159.1 ± 16.1  181.2 ± 14.3 149.7 ± 12.3  NS   
Post  166.9 ± 11.5  160.9 ± 10.3  155.6 ± 9.8 184.8 ± 10.6  29.3 ± 14.6  24.6 ± 14.7   
          (p = 0.28)  (p = 0.54)  p = 0.1 
Neutrophil telomere length corrected for neutrophil count (kb/genome/105 cells) 
Baseline  0.61 ± 0.10  0.82 ± 0.12  0.97 ± 0.18 0.55 ± 0.06  p = 0.25   
Post  0.72 ± 0.08  0.91 ± 0.70  0.63 ± 0.07 0.82 ± 0.08  0.19 ± 0.07  −0.10 ± 0.07   
          (p = 0.015)  (p = 0.17)  p = 0.97 
PBMC telomere length (kb/genome) 
Baseline  103.9 ± 11.6  86.5 ± 11.4  114.1 ± 9.8 75.0 ± 8.2 *  p = 0.03   
st  107.1 ± 11.6  101.9 ± 10.2  96.5 ± 9.7  107.3 ± 10.5  10.5 ± 14.7  5.1 ± 14.5   
          (p = 0.48)  (p = 0.73)   p = 0.46 
PBMC telomere length corrected for PBMC count (kb/genome/105 cells) 
Baseline  1.06 ± 0.14  0.89 ± 0.13  1.18 ± 0.14 0.66 ± 0.11 *  p = 0.03   
Post  1.16 ± 0.15  0.95 ± 0.14  0.99 ± 0.13 1.08 ± 0.14  −0.64 ± 0.14  −0.02 ± 0.14   














. ( ) ost inter e ti e tr il t l l il j
f baseline values in patients taki g n-3 fatty a ids compared with those not taking n-3 fatty
acids. † p = 0.015 for main effect of n-3 fatty acids post-intervention adjusted for bas line values;
(b) Post-intervention plasma F2-isoprostanes in patients taking n-3 fatty acids compared with those
ot taking n-3 fatty acids. † p < 0.001 for main effect of n-3 fatty acids post-intervention adjusted for
baseline values. Values are means ˘ SEM.
There were no significant correlations between PBMC telomere length and PBMC count at
baseline or after the intervention. At baseline, PBMC telomere length corrected for PBMC count was
significantly lower in the n-3 fatty acid + CoQ group compared with CoQ alone (p = 0.03, Table 1).
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Post-intervention, there was no effect of n-3 fatty acids or CoQ on PBMC telomere length corrected for
PBMC count (p = 0.73) and (p = 0.90), respectively, after adjusting for baseline values. There was no
significant interaction between n-3 fatty acids and CoQ that affected PBMC telomere length (Table 1).
3.4. Relationship between Plasma F2-Isoprostanes and Telomere Length
At baseline plasma F2-isoprostanes were not different between the groups: Controls, 1602 (CI
1423, 1780) pmol/L; n-3 fatty acids, 1714 (CI 1539, 1888) pmol/L; CoQ, 1448 (CI 1346, 1550) pmol/L;
and n-3 fatty acids + CoQ. 1479 (CI 1325, 1632) pmol/L. Post-intervention plasma F2-isoprostanes
were: Controls, 1658 (CI 1553, 1764) pmol/L; n-3 fatty acids, 1215 (CI 1119, 1312) pmol/L; CoQ, 1533
(CI 1443, 1624) pmol/L; and n-3 fatty acids + CoQ. 1253 (CI 1156, 1350) pmol/L. In main effects
analysis there was a significant reduction in F2-isoprostanes after n-3 fatty acids (Figure 1B), but no
effect of CoQ on plasma F2-isoprostanes. In regression analysis, after adjusting for baseline values
post-intervention neutrophil telomere length corrected for neutrophil count was negatively related
to post-intervention plasma F2-isoprostanes (β = ´0.242, p = 0.025). The model explained 21.2% of
the variation in neutrophil telomere length corrected for neutrophil count. There was no significant
relationship between post-intervention neutrophil telomere length corrected for neutrophil count and
post-intervention eGFR, blood pressure or hs-CRP. There were no significant associations between
post-intervention PBMC telomere length corrected for PBMC count and post-intervention plasma
F2-isoprostanes or post-intervention eGFR, blood pressure or hs-CRP.
4. Discussion
This study examined the main and interactive effects of n-3 fatty acids and CoQ on neutrophil
and PBMC telomere length in patients with CKD. There was no effect of n-3 fatty acids or CoQ on
telomere length of neutrophils or PBMC. However, n-3 fatty acid but not CoQ supplementation, was
associated with a significant increase in neutrophil telomere length after correcting for neutrophil
count. The effect remained significant after adjusting for age, gender and BMI. The increase in telomere
length (corrected for neutrophil count) was negatively associated with post-intervention plasma
F2-isoprostanes. Telomere length of PBMC corrected for PBMC count was not affected by n-3 fatty
acids or CoQ.
Previous report in several different populations have shown a positive association between
leukocyte count and telomere length [10–12]. In our population with CKD there was a significant
relationship between neutrophil telomere length and neutrophil count post intervention. However,
there was no association between baseline PBMC or neutrophil count with telomere length. Baseline
telomere length measured in neutrophils was poorly correlated with telomere length of PBMC
suggesting that there may be different factors affecting telomere length of these cell types. The majority
of cells in the PBMC fraction are lymphocytes (60%–70%) with monocytes contributing 10%–15% of
cells. Unlike lymphocytes, mature neutrophils and monocytes do not undergo further cell division
and are devoid of telomerase activity. Therefore, changes in telomere length in these cells likely reflects
that of their hematopoietic progenitor cells [27]. Interestingly, it has been reported that n-3 fatty acids
given during pregnancy increased the percentage of cord blood CD34+ progenitor cells [28]. These
myeloid progenitor cells are critical for the development of neutrophils. Whether n-3 fatty acids in our
intervention affected neutrophil progenitor cell phenotype in the same manner and whether this is, in
some way, associated with telomere length is not known.
Our results show that telomere length corrected for neutrophil count was increased after n-3 fatty
acids. Correction of telomere length for cell count can be justified on the grounds of previous reports
indicating telomere length is positively correlated with cell count [10–12]. As mature neutrophils do
not have telomerase, the increase in telomere length (corrected for neutrophil count) may be due to
increased neutrophil clearance (efferocytosis) possibly due to senescence that renders neutrophils
unable to respond to chemoattractants or degranulate. Senescence is accompanied by an increase in
the chemokine receptor CXCR4 on the neutrophil surface that homes neutrophils back to the bone
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marrow where they undergo apoptosis [29]. This could result in a pool of circulating neutrophils that
have less telomere erosion that is highlighted when we correct for neutrophil counts. Critical to this
process of neutrophil clearance are specialised proresolving mediators of inflammation (SPM) that
derive from n-3 fatty acids. These substances promote resolution of inflammation and a return to
homeostasis by increasing neutrophil efferocytosis. In this respect resolvin D1 (RvD1), an SPM derived
from DHA, has been shown to increase expression of CXCR4 and reduce lung injury after a challenge
with lipopolysaccharide [30]. We have shown that n-3 fatty acids but not CoQ increased plasma RvD1
in this trial [31]. This could suggest that when the immune system is directed from an inflammatory
state to resolution and a return to homeostasis, telomere length is affected. n-3 Fatty acids could also
affect telomere length by reducing oxidation in the telomere TTAGGG sequence. In support of this
concept, we have shown that n-3 fatty acids but not CoQ significantly reduced plasma F2-isoprostanes
(markers of lipid oxidation) in this study [32] and report herein a significant negative relationship
between plasma F2-isoprostanes and telomere length (corrected for neutrophil count) accounting for a
significant proportion (21.2%) of the variation in telomere length.
The effect of n-3 fatty acids on telomere length corrected for neutrophil count remained significant
after adjustment for BMI, gender and age, and was not related to changes in blood pressure, GFR
or hs-CRP. Our study was of a relatively short duration and renal function was not altered by either
intervention. We have previously reported reductions in blood pressure, heart rate and serum
triglycerides after n-3 fatty acid supplementation in this study [22]. The sample size for this study was
based on the primary endpoint of blood pressure rather than neutrophil and PBMC telomere length
that were measured as secondary outcomes. Therefore, a larger trial of longer duration of n-3 fatty acid
supplementation will be required to determine whether effects on neutrophil telomere length associate
with a reduction in CVD in patients with CKD.
Our study is the first to measure and compare telomere length in neutrophils and mononuclear
cells after n-3 fatty acid supplementation in patients with CKD. Other studies examining the effect of
n-3 fatty acids on telomere length include a prospective cohort study in aging patients with coronary
heart disease that showed an inverse association between n-3 fatty acids measured in blood at baseline
and the rate of telomere shortening over 5 years [33]. There have been two reports of controlled
studies of n-3 fatty acids on telomere length. A small randomised controlled study of n-3 fatty acids
versus linoleic acid in elderly individuals with mild cognitive impairment did not show any effect
of n-3 fatty acids (~2 g/day) given for 6 months on telomere length, but reported that increased
erythrocyte DHA associated with reduced telomere shortening [34]. A larger randomised controlled
trial in healthy men and women compared the effects of two doses of n-3 fatty acids (1.25 g/day and
2.5 g/day) for 4 months on lymphocyte telomere length, telomerase activity, and oxidative stress
assessed from measurement of plasma F2-isoprostanes [35]. The trial demonstrated a significant fall in
plasma F2-isoprsoatnes after n-3 fatty acids with no effect on lymphocyte telomere length or telomerase
activity. However, telomere length was inversely associated with n-6:n-3 fatty acid ratio [35]. The
reduction in oxidative stress is consistent with the data from our study that showed a significant
reduction in plasma F2-isoprostanes after n-3 fatty acids [32]. In addition, our study provides evidence
that post-intervention plasma F2-isoprostanes are negatively related to telomere length accounting for
a significant proportion (21.2%) of the variation. These findings suggest that reducing oxidative stress
may prevent telomere shortening as has been suggested in the literature [36–39].
Post-intervention PBMC telomere length was not significantly influenced by n-3 fatty acids or CoQ
either before or after adjustment for PBMC count. The differences observed between DNA obtained
from neutrophils and PBMC could in part reflect the relative turnover of the cell types. Neutrophil
half-life is estimated to be 6–8 h [29] whereas the half-life of monocytes and lymphocytes range is
1–3 days [40] and up to 80 days [41], respectively. Our findings suggest that any effect of n-3 fatty acids
on telomeres may differ according to the cell type and turnover. In a recent study of samples collected
from human cadavers, telomere length of leucocytes was compared with that of 11 different tissues.
The study showed that leukocyte telomere length was poorly correlated with telomere length in a
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variety of tissues [42]. We measured telomere length in a mixed population of PBMC that included
monocytes as well as T and B lymphocytes. Therefore, any changes in PBMC telomere length would
likely have been influenced by changes in the proportion of monocytes and lymphocyte subsets, that
have been shown to be very heterogeneous in terms of telomere length and telomerase activities [43]
Our ability to detect changes in telomere length of PBMC may also have been influenced by the large
proportion of patients who were treated with ACE inhibitors. These agents are known to suppress
lymphocyte function [44], and to reduce markers of DNA oxidation [45] in patients with CKD.
We found no effect of CoQ on neutrophil or PBMC telomere length or oxidative stress assessed
by plasma F2-isoprostanes in contrast to a previous study in a rabbit model of atherosclerosis that
showed CoQ protected against oxidation of lymphocyte DNA [46]. However, that study provided
a relatively high dose of CoQ (25 mg/kg) to animals that were fed a high fat diet. A small open
trial in humans showed that CoQ given as 6 mg/kg/day for 4 weeks reduced lymphocyte DNA
8-hydroxydeoxy-guanosine [47].
5. Conclusions
In conclusion, n-3 fatty acid supplementation in patients with CKD was associated with an
increase in neutrophil telomere length that was corrected for neutrophil count. The finding that
post-intervention telomere length negatively associated with plasma F2-isoprostanes, further suggests
the effect of n-3 fatty acids on telomere length may be due, in part, to a reduction in oxidative stress.
Long term studies of the effects of n-3 fatty acids in CKD patients are required to confirm the present
findings and determine if changes in telomere length may be associated with a reduction in CVD risk
in patients with CKD.
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